The EPS projection of Bristol-Myers Squibb Company (NYSE:BMY) for quarter ended 2016-09-30 is $0.64. A week before, the EPS forecast was $0.64 against target of $0.64, a month earlier. This estimate stood at $0.64 60 days earlier versus forecast of $0.64 90 days earlier, confirming a deviation of 0%.
Bristol-Myers Squibb Company (NYSE:BMY) reported that 18 days ago, the positive EPS revisions were 1 and negative revisions at 1.
In last week, the per-share earnings was lowered 0 times and 0 times positively. In last 120, 60, 30 and 90 days the positive revisions were 5, 4, 0 and 5, respectively.
The downgrade of EPS estimates for Bristol-Myers Squibb Company (NYSE:BMY) in the preceding 120, 60, 30 and 90 days were 0, 0, 0 and 0, in that order.
As per the latest update, for the quarter closed 1, the EPS estimate of Bristol-Myers Squibb Company (NYSE:BMY) was $0.64. This projection was computed after accounting 10 calls. As reported on 2016-04-28 the EPS was $0.74. The change was $0.08, demonstrating a percentage deviation of 12.12%. The projections confirmed a standard deviation of 0.03.
Quarterly Sales Estimates
For the fiscal 2016, the yearly sales target for Bristol-Myers Squibb Company (NYSE:BMY) stands at $4865.7 and the median estimate at $4840.1. Almost 3 analysts announced their estimates.
The highest estimate is $4962 while the lowest target is $4795 showing standard deviation of 86.393%.
As many as 3 analysts released sales estimates reised in upside while 3 reduced sales estimates, demonstrating a deviation of 1.946%.
In last month, 3 revised sales number projection on upside while 3 lowered the sales target, demonstrating a deviation of 1.946%.
A quarter ago, 3 hiked sales estimations and 3 reduced sales forecast. Bristol-Myers Squibb Company (NYSE:BMY) stated that the change in forecast was 5.58%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...